![\"Chairman,](\"https:\/\/www.taimei.com\/site\/wp-content\/uploads\/2024\/10\/f0ba8277dbce9885b982553263215261.jpg\")
<\/figure>\n\n\n\nChairman, Executive Director, and CEO of Taimei Technology, Mr. Zhao Lu (left), along with Executive Director, General Counsel, and Board Secretary, Ms. Ni Xiaomei (right), rang the bell to mark the market opening.<\/p>\n\n\n\n
At the listing ceremony, Mr. Zhao Lu, Chairman, Executive Director, and General Manager of Taimei Technology, along with Ms. Ni Xiaomei, Executive Director, Legal Director, and Board Secretary, struck the gong to mark the company\u2019s new journey. Attendees included company executives, shareholder representatives, sponsors, and intermediaries involved in the IPO, all gathering to witness this significant milestone in Taimei Technology\u2019s development. Mr. Zhao Lu, Chairman, Executive Director, and General Manager of Taimei Technology Since its founding in 2013, Taimei Technology has focused on delivering advanced digital solutions for the pharmaceutical and medical device industries, benefiting patients worldwide. As of March 31, 2024, Taimei Technology provides over 40 software products and digital services across trial design and management, patient recruitment and follow-up, data collection, and analysis\u2014addressing the diverse needs of various organizations and roles.<\/p>\n\n\n\n To address industry collaboration challenges, Taimei Technology developed two digital collaboration platforms: TrialOS and PharmaOS. These platforms effectively connect hospitals, pharmaceutical companies, third-party service providers, patients, and regulatory bodies, creating a unified standard for data flow, process integration, and resource sharing. This approach supports the digital transformation of the industry, enhancing R&D efficiency and post-market performance in pharmaceuticals and medical devices for shared value creation.<\/p>\n\n\n\n By March 31, 2024, Taimei Technology has served over 1,400 pharmaceutical companies and CROs, including 21 of the top 25 global pharmaceutical companies and 90 of China\u2019s top 100 pharmaceutical innovators. The company has also partnered with over 700 certified drug trial institutions, with more than 80% being top-tier hospitals. Based on the number of clients, Taimei Technology is the most widely adopted digital solutions provider in China\u2019s pharmaceutical R&D and marketing sectors.<\/p>\n","protected":false},"excerpt":{"rendered":" Reading Time: <\/span> 2<\/span> minutes<\/span><\/span>Chairman, Executive Director, and CEO of Taimei Technology, Mr. Zhao Lu (left), along with Executive Director, General Counsel, and Board Secretary, Ms. Ni Xiaomei (right), rang the bell to mark the market opening.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[16],"tags":[],"custom-tag-products":[],"custom-tag-solution":[],"custom-tag-type":[],"class_list":["post-11403","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":{"event_start_day":null,"event_end_date":null,"event_description":"Presenting, sponsoring, and\/or exhibiting? Booth #, venue name, topic to learn about","event_website":"","physical_location_address":""},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/posts\/11403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/comments?post=11403"}],"version-history":[{"count":5,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/posts\/11403\/revisions"}],"predecessor-version":[{"id":11422,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/posts\/11403\/revisions\/11422"}],"wp:attachment":[{"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/media?parent=11403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/categories?post=11403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/tags?post=11403"},{"taxonomy":"custom-tag-products","embeddable":true,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/custom-tag-products?post=11403"},{"taxonomy":"custom-tag-solution","embeddable":true,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/custom-tag-solution?post=11403"},{"taxonomy":"custom-tag-type","embeddable":true,"href":"https:\/\/www.taimei.com\/en\/wp-json\/wp\/v2\/custom-tag-type?post=11403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
In his speech, Mr. Zhao Lu stated, “Our successful entry into the Hong Kong capital market marks a new starting point for Taimei Technology. With the strength of the capital market behind us, we will remain committed to our mission of \u2018harnessing digital power to make healthcare accessible.\u2019 We will continue to innovate our products and services, improve operational quality and efficiency, and support the development and accessibility of effective medicines and medical devices, all while giving back to our investors for their trust and support.”<\/p>\n\n\n\n![\"\"](\"https:\/\/www.taimei.com\/site\/wp-content\/uploads\/2024\/10\/37bb72e58ac4f82763ae0475130b20e9.jpg\")
<\/figure>\n\n\n\n
<\/p>\n\n\n\n